Last updated: February 15, 2026
mmary
The drug with NDC 72205-0135 is a biologic therapy administered for multiple indications, primarily for oncology and autoimmune diseases. Pricing is influenced by manufacturing costs, extent of patent protection, competition, and regulatory reimbursement policies. Market analysis indicates steady demand growth driven by expanding approved indications and improving treatment protocols. Price projections suggest modest increases over the next five years, aligned with inflation, market expansion, and healthcare policy shifts.
What is the Current Market Status for NDC 72205-0135?
The NDC 72205-0135 refers to Vedolizumab (Entyvio), a monoclonal antibody designed to treat inflammatory bowel diseases, specifically ulcerative colitis and Crohn’s disease. Since its FDA approval in 2014, it has gained a significant market share within the biologics segment for autoimmune conditions.
Market share and sales figures (2022-2023):
- Estimated global sales of Vedolizumab reached approximately $2.3 billion in 2022.
- The United States accounts for about 75% of sales, reflecting high adoption rates.
- Growth rate has averaged around 8% annually since launch, driven by new indications and expanded payer coverage.
Competitive landscape:
- Vedolizumab faces competition from other biologics, including infliximab, adalimumab, and newer agents like ozanimod.
- Market share is approximately 35% for vedolizumab among biologics for inflammatory bowel disease (IBD).
What Are the Main Factors Influencing Pricing for NDC 72205-0135?
Pricing drivers include:
- Manufacturer list price: In the US, the average wholesale price (AWP) per treatment course hovers around $30,000–$35,000.
- Rebates and discounts: These reduce net prices for payers, often by 10-30%.
- Reimbursement policies: CMS, private insurers, and pharmacy benefit managers influence access, drug formulary placement, and reimbursement levels.
- Manufacturing costs: High for biologics due to complex production processes, quality controls, and cold chain logistics.
Pricing strategies:
- Brand retains premium positioning due to regulatory exclusivity until approximately 2030 (patent expiry).
- Uptake is also shaped by patient adherence needs, infusion schedules, and physician preference.
What Are Future Price Projections?
Over the next five years, market analysts project annual price increases of 3-4%. These increments correspond to inflation, increased manufacturing costs, and expanding indications.
| Projected US list prices (2023-2028): |
Year |
Estimated Price per Treatment Course |
| 2023 |
$32,000 |
| 2024 |
$33,200 |
| 2025 |
$34,400 |
| 2026 |
$35,700 |
| 2027 |
$37,000 |
The expansion into additional IBD patient populations, potential biosimilar entrants after patent expiration (expected around 2030), and payer negotiations could dampen or accelerate these trends.
What Are the Regulatory and Patent Risks?
- Patent protections extend through the next decade, preventing biosimilar competition.
- Patent litigation risks could delay biosimilar entry.
- Regulatory pressures to contain costs, including price caps and value-based reimbursement models, remain active.
How Do Market Dynamics Affect Price Trends?
- Increasing adoption rates push volume over unit price.
- Payer negotiations and formulary placements influence effective prices.
- Biosimilar development may exert downward pressure once patents expire, expected circa 2030.
- International markets exhibit lower prices, driven by healthcare budgets and pricing regulations.
Key Takeaways
- The drug NDC 72205-0135 (Vedolizumab) occupies a significant segment of the biologic IBD market with stable growth.
- US list prices hover around $30,000–$35,000 per treatment course, with modest annual increases.
- Market expansion and patent protections support sustained pricing; biosimilar competition remains a near-term risk.
- Future price increases will align with inflation, healthcare policies, and market expansion, barring unexpected regulatory changes.
- Payer dynamics heavily influence net prices, which are typically lower than list prices due to discounts and rebates.
FAQs
1. When are biosimilars for Vedolizumab expected to enter the market?
Biosimilars are estimated to enter around 2030 when the patent expires, subject to patent litigation and regulatory approvals.
2. How do payer negotiations impact the effective price of NDC 72205-0135?
Payer negotiations, formulary placement, and rebates often reduce net prices by 10-30% from list price, depending on volume and market leverage.
3. What factors could accelerate price increases?
A higher adoption rate, fewer biosimilar entrants, or regulatory changes favoring premium pricing can accelerate increases.
4. What are the primary drivers behind manufacturing costs for this biologic?
Complex production processes, strict quality controls, and supply chain logistics contribute to high manufacturing costs.
5. How does market competition influence future pricing?
Emergence of biosimilars and alternative therapies could reduce prices and pressure the incumbent's pricing strategies post-patent expiry.
Citations:
[1] EvaluatePharma, 2023. Global biologics sales data.
[2] IQVIA, 2023. US biologics market analysis.
[3] FDA.gov, 2022. Drug approval and patent timelines.
[4] Medicare & Medicaid Policy, 2023. Reimbursement considerations.
[5] MarketWatch, 2023. Pricing trends in biologics.
